Literature DB >> 22543906

Serum-soluble urokinase receptor concentration in primary FSGS.

Rutger J H Maas1, Jack F M Wetzels2, Jeroen K J Deegens2.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22543906     DOI： 10.1038/ki.2012.32

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  38 in total

Review 1.  Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Authors:  Djillali Sahali; Kelhia Sendeyo; Melanie Mangier; Vincent Audard; Shao Yu Zhang; Philippe Lang; Mario Ollero; Andre Pawlak
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

2.  The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?

Authors:  Björn Meijers; Ben Sprangers
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

3.  Glomerular disease: 'suPAR'-exciting times for FSGS.

Authors:  J Ashley Jefferson; Charles E Alpers
Journal:  Nat Rev Nephrol       Date:  2013-02-05       Impact factor: 28.314

4.  Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome.

Authors:  Jutta Gellermann; Franz Schaefer; Uwe Querfeld
Journal:  Pediatr Nephrol       Date:  2014-08-17       Impact factor: 3.714

5.  Reply: Measurement of serum suPAR is not ready for clinical use.

Authors:  Jeroen Deegens; Jack Wetzels
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

Review 6.  Minimal change disease and idiopathic FSGS: manifestations of the same disease.

Authors:  Rutger J Maas; Jeroen K Deegens; Bart Smeets; Marcus J Moeller; Jack F Wetzels
Journal:  Nat Rev Nephrol       Date:  2016-10-17       Impact factor: 28.314

Review 7.  Update on the treatment of focal segmental glomerulosclerosis in renal transplantation.

Authors:  Maria Messina; Ester Gallo; Alberto Mella; Fabiola Pagani; Luigi Biancone
Journal:  World J Transplant       Date:  2016-03-24

Review 8.  Focal Segmental Glomerulosclerosis.

Authors:  Avi Z Rosenberg; Jeffrey B Kopp
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-27       Impact factor: 8.237

9.  Regarding Maas's editorial letter on serum suPAR levels.

Authors:  Howard Trachtman; Debbie S Gipson; Frederick Kaskel; Gian M Ghiggeri; Christian Faul; Vineet Gupta; Alessia Fornoni; George W Burke; David B Thomas; Laura Barisoni; Franz Schaefer; Changli Wei; Jochen Reiser
Journal:  Kidney Int       Date:  2012-08       Impact factor: 10.612

Review 10.  Recent progress in the pathophysiology and treatment of FSGS recurrence.

Authors:  P Cravedi; J B Kopp; G Remuzzi
Journal:  Am J Transplant       Date:  2013-01-11       Impact factor: 8.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.